Amira M.  Abo-Youssef, Basim A.S.  Messiha, 
    The Protective Effect of Dexamethasone, Aspirin and Bromocriptine on Hepatic Ischemia/Reperfusion Injury in Rats,
    Research Journal of Pharmacology,
    Volume 8,Issue 2,
    2014,
    Pages 6-13,
    ISSN 1815-9362,
    rjpharm.2014.6.13,
    (https://makhillpublications.co/view-article.php?doi=rjpharm.2014.6.13)
    Abstract: This study aimed to investigate the protective effects of 
  dexamethasone, aspirin and bromocriptine on hepatic ischemia/reperfusion-induced 
  liver injury. About 60 male Wistar Albino rats were randomly assigned to 6 groups 
  of 10 rats each. Group 1 served as negative control, group 2 served as hepatic 
  I/R control injury. Rats in groups 3-6 received N-acetylcysteine (standard, 
  100 mg/kg/day, i.p.), dexamethasone (5 mg/kg/day, i.p.), aspirin (10 mg/kg/day, 
  i.p.) and bromocriptine (10 mg/kg/day, i.p.), respectively for 3 consecutive 
  days prior to ischemia. All animals were fasted for 12 h, anaesthetized with 
  thiopental and underwent midline laparotomy. The portal vein, hepatic artery 
  and bile duct (portal triad) were clamped by mini-artery clamp for 30 min followed 
  by reperfusion for 30 min. At the end of the experiment, blood samples were 
  withdrawn for estimation of serum Alanine Transaminase (ALT) and Aspartate Transaminase 
  (AST) activities in addition to assessment of hepatic Thiobarbituric Acid Reactive 
  Substances (TBARS), Glutathione (GSH), Myeloperoxidase (MPO) and total nitrate/nitrite 
  (NO<SUB>x</SUB>) production, as well as histopathological examination. Dexamethasone, 
  aspirin and bromocriptine significantly ameliorated hepatic I/R injury as evidenced 
  by significant reduction in serum ALT and AST enzyme activities. Dexamethasone, 
  aspirin and bromocriptine markedly reduced hepatic oxidative stress biomarkers 
  as compared to control I/R injury. The inflammatory mediators MPO and NO<SUB>x</SUB> 
  levels in liver were also significantly reduced after treatment with dexamethasone, 
  aspirin and bromocriptine. In accordance, a marked improvement of histopathological 
  findings was observed with any of the 3 treatments. Dexamethasone, = aspirin 
  and bromocriptine seem to offer protection against hepatic ischemia/reperfusion-induced 
  liver injury and are promising for further clinical trials.
    Keywords: hepatic oxidatine;bio markers;Histopathological;bromocriptine;treatment